ForwardVue Pharma, Inc.

1.1 History & Prior Art

Carboxyamidotriazole (CAI, also known as CTO, L-651582, and RFE-007) is a synthetic small molecule with anti-angiogenic properties first characterized at the National Cancer Institute decades before ForwardVue was founded. CAI blocks the ORAI1 channel — a component of the CRAC (calcium release-activated calcium) complex that co-localizes with VEGFR2 — and additionally interferes with Wnt-Norrin, FGF, integrin, and PDGF angiogenic pathways. The TVST 2025 primary source attributes CAI's anti-angiogenic action specifically to ORAI1 blockade and these adjacent pathways; STIM1 does not appear in the paper.

CAI accumulated a human safety record through five registered NCI-sponsored oncology trials across multiple decades (ClinicalTrials.gov NCT00019019, NCT00004146, NCT01954030, NCT00005045, NCT00003869). These registered studies enrolled 383 patients in total. The largest, NCT00003869, was a Phase 3 trial in Stage III and IV non-small cell lung cancer that enrolled 186 patients; oral CAI did not advance to approval. The prior human program establishes a systemic safety baseline for the compound but does not support the intravitreal route or the retinal indications ForwardVue pursues.

The molecule's ophthalmic history runs longer than the deck discloses. Alan Franklin served as Chief Medical Officer at RFE Pharma — a predecessor company — from 2005 through October 2019, fourteen years working on the same compound against the same retinal diseases. Both issued patents the deck presents as ForwardVue's IP (US 8,614,235 and US 9,629,826) came to ForwardVue from predecessor entities (RFE Pharma Corp. and Gen Pharma Holdings, LLC) in 2021. ForwardVue is not a first-principles biotech; it is the latest iteration of a program with a fourteen-year prior history that the deck does not name.

1.2 Differentiation

FVP-002 differs from the prior RFE oral CAI program in route and formulation: a bioresorbable PLGA implant for intravitreal delivery replaces systemic oral dosing, hitting the retina directly while avoiding the gastrointestinal toxicity that limited systemic CAI in oncology. The differentiation against current standard of care rests on VEGF-independence — if FVP-002 suppresses neovascularization through the calcium-channel axis, it may work in patients refractory to ranibizumab, aflibercept, or faricimab. This is a scientifically coherent hypothesis with one peer-reviewed preclinical paper supporting it.

The IP differentiation the deck implies — two issued patents, a PCT covering the lead asset — does not survive contact with current USPTO records. Both issued patents expired in 2025. The PCT covering FVP-002 (WO 2025/075991) remains PCT-only with an unresolved US national-phase status.

2.1 Target Biology

CAI targets the ORAI1 channel, the plasma-membrane subunit of the CRAC (calcium release-activated calcium) channel complex. In retinal endothelial cells, ORAI1-mediated calcium entry co-localizes with VEGFR2 signaling; CAI's blockade reduces tube formation and endothelial cell migration upstream of the VEGF pathway. The mechanistic hypothesis: ORAI1 inhibition plus the adjacent Wnt-Norrin/FGF/integrin/PDGF pathways CAI also touches reduce neovascularization independently of VEGF — a result that, if borne out, makes FVP-002 complementary to rather than redundant with anti-VEGF biologics. The published primary source names ORAI1 specifically and does not name STIM1, the ER-side calcium sensor that some prior CAI literature pairs with ORAI1 in the broader SOCE framing.

The TVST 2025 paper (DOI 10.1167/tvst.14.3.21) demonstrated FVP-002 activity in a mouse choroidal neovascularization model and a rabbit vascular-leakage model. These experiments confirm that the CAI PLGA implant releases drug into the vitreous at concentrations that suppress neovascularization in short-duration animal models.

2.2 Validation Layers

Three lines of evidence support the CAI mechanism — only one of them external to ForwardVue's network:

1. Human safety from the oral oncology program. Five NCI-sponsored trials (n=383 registered) established that systemic CAI is tolerable. This layer is route-mismatched — oral systemic delivery versus intravitreal implant — and does not validate efficacy in retinal disease.

2. TVST 2025 preclinical (DOI 10.1167/tvst.14.3.21). A single peer-reviewed paper from a UAB lab Franklin is affiliated with demonstrates in-vitro release to 56 days and in-vivo suppression of vascular leakage in rabbit to 120 days. This is the only published evidence for the FVP-002 formulation.

3. Established ORAI1/CRAC literature. The target biology validates outside ForwardVue's work. ORAI1 channel biology and CRAC-complex regulation are well-characterized pathways in retinal physiology, with peer-reviewed mechanistic literature published independently of any ForwardVue-affiliated group.

The independence problem confines itself to the second layer: every published retinal CAI study from 2005 to 2025 traces to two overlapping labs — the Doheny/USC group and the UAB-Grant-Franklin group — with no external replication. A mechanism that has attracted no independent laboratory investigation over two decades carries a reproducibility question that only third-party replication will close.

2.3 Target Validation Score

ForwardVue's lead molecule targets the ORAI1 calcium channel in retinal endothelial cells. The target-validation question is whether ORAI1-blockade in wet AMD rests on enough independent evidence to clear a pre-IND threshold. The five dimensions below score 0–3 each (0 = absent, 1 = thin, 2 = supported, 3 = strong); total over 15 places this program at 7/15 (47%) — moderate validation; mechanism-plausible but class-precedent-thin.

Interpretation. A 7/15 places ORAI1 in wet AMD in the "plausible-but-unproven" tier — sufficient to support a pre-IND program, insufficient to anchor a commit-stage thesis without a human proof-of-concept readout. The single most-load-bearing future event for the score is class precedent: an approved ORAI1 modulator in any indication (current pipeline includes immunology candidates) would lift this dimension from 0/3 to 2/3 and move the total to 9/15 (60%). Absent class precedent, the program's validation depends on a successful first-in-human readout in anti-VEGF-refractory patients.

3.1 Data Summary

FVP-002 has zero ForwardVue-sponsored registrations on ClinicalTrials.gov. The company announced a Phase 2 trial for retinal disorders in July 2021 (AdisInsight entry 800064720); that trial has not registered in nearly five years. AdisInsight's most recent update (2025-08-28) reads "No recent reports of development identified for preclinical development in Retinal-disorders in USA (Intravitreous, Injection)."

The published preclinical evidence is a single paper: Li-Calzi, Fujihashi, Franklin et al., TVST 2025 Vol 14 No 3 Article 21 (DOI 10.1167/tvst.14.3.21; PMID 40131299; PMC11951051; open access). The paper runs mouse choroidal neovascularization experiments and a rabbit vascular-leakage cohort. No human data exist for the intravitreal route.

Mouse CNV efficacy. At day 7 post-treatment, CAI 1.0 μg reduced neovascularization to 24.87 ± 2.49% of saline control (n=5, P=0.0001). CAI 0.5 μg reached 49.27 ± 2.89% (n=4, P=0.0066). At the highest dose tested, CAI 2.0 μg reached 70.43 ± 9.08% (n=3, P=0.295) — an inverted dose-response that the paper does not address. At day 14, CAI 1.0 μg showed 30.52 ± 7.01% (n=3, P=0.030). Aflibercept at the comparator dose reached 80.29 ± 7.93% at day 7 (P=0.388, not significant vs saline) and 41.29 ± 6.95% at day 14 (P=0.052, not significant). The mouse data establish anti-angiogenic activity at low microgram doses; the n=3 groups, the inverted dose-response, and the comparator's failure to separate from saline at both timepoints are design limitations of a screening-stage rodent study.

Rabbit vascular-leakage cohort. The investigators injected VEGF on days 23 and 53 into rabbit vitreous, then measured fluorophotometry at day 30 and day 60. At day 30, saline = 178.12 ng/mL ± 30.55 (n=5), aflibercept = 84.40 ng/mL ± 10.45 (n=6, P=0.0244 vs saline), and CAI = 80.16 ng/mL ± 15.02 (n=9, P=0.0141 vs saline). Both drugs separated from sham at day 30. At day 60, saline = 200.03 ng/mL ± 123.64 (n=4 — one sham animal lost between day 30 and day 60), aflibercept = 107.06 ng/mL ± 18.09 (n=5, P=0.431 vs saline — not significant), and CAI = 45.572 ng/mL ± 10.39 (n=9, P=0.078 vs saline — not significant). The only significant day-60 comparison is CAI vs aflibercept (P=0.0132, 2.35-fold ratio). That comparison is confounded by design: a sustained-release CAI implant still delivering drug at day 60 against a single-dose aflibercept administered on day 0, depleted by week 8 (vitreous t½ ≈5–10 days). The day-60 finding measures duration of action, not peak potency. The abstract's "significantly reduced neovascularization" framing references this CAI-vs-depleted-aflibercept comparison; CAI vs the disease state (sham) at the primary endpoint does not reach significance. The rabbit model also simulates DME pathophysiology — VEGF-induced vascular permeability — not the choroidal neovascularization characteristic of wet AMD, which the company targets as the primary indication.

In-vitro release ran to 56 days (the last x-axis tick on the release curve), with cumulative API release at approximately 60–65% at that endpoint (visual estimate from Figure 1A; exact percentage not stated in the text). The Methods specify polymers chosen for 3-month degradation. The Discussion's "feasibility for 6-month sustained release of bioactive doses" is a forward extrapolation, not a measurement. The in-vivo rabbit cohort (Group C) extends to day 120; PK was not measured.

CAI's prior human exposure runs across five registered NCI oncology trials with results. Total registered enrollment across these five studies was 383 patients. The Phase 3 NSCLC trial (NCT00003869; N=186) completed without advancing oral CAI to approval. The company's PRNewswire release states CAI "has been administered to over 900 patients systemically to treat advanced cancer"; ClinicalTrials.gov confirms 676+ subjects across 7 NCI trials with reported enrollment, with the residual ~224 patients presumably traced to pre-1997 Phase 1 work that predated mandatory registry submission (Kohn 1997 PMID 9164210; Berlin 1997 PMID 9053505). Systemic oral CAI does not provide a route-matched human safety baseline for an intravitreal implant.

3.2 Source vs. Company Claims

The TVST 2025 paper itself contains four internal contradictions documented in this analysis:

The deck's durability framing departs from what the paper measures across each cited slide:

The website (forwardvuepharma.com) makes the strongest claim — "durable administration up to 12 months" — with no support in the published paper or any other primary source.

4.1 FAERS Disproportionality

FAERS disproportionality metrics (PRR, ROR) cannot be computed at usable confidence for carboxyamidotriazole. The FDA openFDA drug event API returned only 13 total reports under the medicinalproduct "carboxyamidotriazole" across all routes and indications as of 2026-05-11. By convention, the minimum thresholds for a defensible PRR signal are at least three reports of a specific event AND a chi-square statistic of at least 4. Only one event term (HYPONATRAEMIA, n=3) clears the first threshold; the small exposure denominator (a+b = 13) makes every PRR estimate noise-dominated and the chi-square gates fail.

What the raw FAERS aggregate looks like:

Critically, zero of these 13 reports list an ophthalmic or intravitreal route. Every report traces to systemic oral CAI in advanced-cancer indications across the NCI oncology trials and their post-trial follow-up. The route-matched safety database for intravitreal CAI is empty. This is structurally expected for a pre-IND molecule that has never reached human ophthalmic exposure — and it bounds the safety claim ForwardVue can make in investor materials. The deck's slide-12 "Human Safety Data Profile" framing aggregates a 13-report systemic-oncology FAERS signature with a 676+/900-subject NCI trial history; that aggregate is route-mismatched for FVP-002. FVP-002's first-in-human study will generate the first intravitreal-route safety data on record.

Source: FDA openFDA drug event API (api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:carboxyamidotriazole), retrieved 2026-05-11; 13 reports total / 8 distinct AE terms / 0 ophthalmic-route reports.

4.2 Class-Wide Signals

Oral CAI was generally tolerated in NCI oncology trials, with grade 1–2 adverse events predominant and no black-box warnings or withdrawal-for-safety findings. The Phase II 2003 study (PMID 14645425) reports: "CAI was well tolerated, with mostly grade 1 to 2 toxicity. Grade 3 events included fatigue (5%), vomiting (2%), neutropenic fever (2%), and neutropenia (2%)." Earlier Phase I studies (Berlin 1997 PMID 9053505; Kohn 1997 PMID 9164210) characterize the systemic-oral pharmacokinetics — high serum plasma protein binding (over 99%) and variable absorption — that ultimately limited oral CAI's efficacy in oncology rather than its safety. Omuro 2018 (PMID 29683790) tested CAI orotate plus temozolomide in glioblastoma without flagging new safety signals. The intravitreal route eliminates systemic GI exposure and grounds the FVP-002 reformulation rationale.

Intravitreal PLGA bioresorbable implants as a delivery class carry an established safety precedent. Ozurdex (dexamethasone PLGA implant) achieved FDA approval through the GENEVA Phase 3 program (Haller 2010 Ophthalmology, N=1,267), validating the PLGA matrix as a drug-delivery system in the posterior segment. Susvimo (ranibizumab via port delivery, BLA 761197, FDA 2021) is the closest sustained-release intravitreal precedent, with a labeled 24-week refill interval. The standing class signal is Beovu (brolucizumab, Novartis) — FDA-approved 2019-10-07, label updated June 2020 to add retinal vasculitis and vascular occlusion warnings. The Beovu episode is the cautionary precedent: new IVT agents can accumulate immune-mediated findings post-approval, and any FVP-002 first-in-human study must be designed for that surveillance.

4.3 Disqualifying Findings

No single safety finding from the CAI pharmacology literature disqualifies FVP-002 on its own. The safety question at this stage is the absence of intravitreal-route human safety data that a first-in-human study will need to generate. Three structural observations frame the safety risk envelope:

Route-mismatch in the deck's safety framing. The deck slide 12 cites "Human Safety Data Profile" alongside a 900-subject systemic-oncology denominator. Those 676+ ClinicalTrials.gov-registered NCI enrollees received oral CAI for advanced cancers; their safety data do not transfer to an intravitreal PLGA implant. The route-matched safety database is empty.

Inverted dose-response in the mouse CNV model (CAI 2.0 μg P=0.295 NS vs CAI 1.0 μg P=0.0001). Unexplained inverted dose-response in a screening-stage preclinical model is a warning sign for either an off-target hit at higher local concentration or a formulation issue at the proposed therapeutic dose. The TVST 2025 paper does not discuss this finding. The IND-enabling toxicology package will need to address whether the inverted curve is a CAI ocular pharmacology issue, a PLGA-release-rate issue, or a model-noise artifact at n=3.

The Beovu post-approval class signal. Brolucizumab is the cautionary precedent for an FDA-approved single-mechanism IVT agent that accumulated retinal-vasculitis findings only after the label issued. FVP-002 enters the clinic in the same general territory; FIH study design must include monitoring for immune-mediated retinopathy and intraocular inflammation, with stopping rules. The Beovu episode does not disqualify FVP-002; it sets the surveillance bar.

5.1 Chain of Title

ForwardVue's IP estate consists of assignments from two predecessor entities, a PCT application co-invented with a departed CEO, one newly granted off-thesis US patent, and an abandoned application family.

US 8,614,235 B2 ran a two-step assignment chain: a 2021-09-13 corrective assignment from RFE Pharma LLC to RFE Pharma Corp, then on 2021-09-29 from RFE Pharma Corp. to ForwardVue Pharma (USPTO reel/frame 57639/743). US 9,629,826 B2 assigned from Gen Pharma Holdings, LLC to ForwardVue Pharma on 2021-05-27 (USPTO reel/frame 56369/72). Both assignments were clean title transfers with no encumbrances noted in the assignment records.

WO 2025/075991 A1, the lead-asset PCT covering the bioresorbable PLGA implant, names Alan Franklin and Bob Katz as co-inventors. Katz departed ForwardVue in March 2026. His inventive contribution to the implant device, if substantial, creates potential inventorship-invalidity exposure under US patent law to the extent any post-departure obligations were not properly addressed. No confirmation of inventor-assignment agreements from Katz appears in the public record.

US 12,594,262 B2 issued 2026-04-07 from application US 17/785,842 (pre-grant publication US 2023/0024928 A1). The patent — titled "CAI nanoemulsions" — covers a PLGA-CAI nanoemulsion formulation for inflammatory optic neuropathies and AMD, with adjusted expiration 2043-05-15. ForwardVue is the named assignee. This patent does not cover the lead-asset implant; it covers the off-thesis nanoemulsion suspension route. Adversarial verification (2026-05-07) corrected this asset's status from PENDING to GRANTED — a correction the canonical record now reflects.

5.2 Maintenance & Lapse Risk

Both issued patents — one covering AMD/DR CAI suspension and one covering uveitis sustained-release formulation — expired in 2025 and 2026. ForwardVue holds zero in-force US patents on FVP-002 as of 2026-05-11.

US 8,614,235 B2 expired at statutory term-end. The 20-year statutory term ran out 2025-09-26 (20 years from the earliest non-provisional 11/235,795 filed 2005-09-26). USPTO recorded the formal lapse 2026-01-26 when the 12th-year fee window closed unpaid; revival is moot — the statutory term has run.

US 9,629,826 B2 expired 2025-06-02 when ForwardVue failed to pay the 7.5-year (8th-year) maintenance fee due 2025-04-25. The lapse forfeited approximately ten years of remaining statutory life (statutory term-end 2035-10-15). The 4th-year fee in April 2021 also crossed into the surcharge window (M2554 dated 2021-04-20), establishing a two-strike pattern of late payment under ForwardVue tenure. A 37 CFR 1.378(b) revival petition is theoretically available (unpaid fee, $1,050 small-entity revival surcharge, statement of unintentional delay), but reviving US 9,629,826 restores uveitis-indication coverage, not FVP-002 lead-asset coverage.

WO 2025/075991 A1 carries a 30-month US national-phase deadline from its priority date of 2023-10-03 — landing 2026-04-03. The USPTO Open Data Portal API (api.uspto.gov/api/v1/patent/applications/search, query "ForwardVue", retrieved 2026-05-11) returned the PCT record with applicationStatusCode: 566, last event MP210 (Mail International Search Report, 2024-12-16), and no 371C (national phase entry) event in eventDataBag. The deadline passed 38 days before retrieval. A late-entry petition under 37 CFR 1.137 (unintentional delay, no hard cutoff) remains technically available; none appears on record as of 2026-05-11. FVP-002 lead-asset US protection depends solely on this PCT achieving late-entry national-phase status.

Two material inventor and claim-scope facts qualify how investors should read the issued portfolio. US 9,629,826's sole inventor is Sunil Gupta — not Alan Franklin. The patent was originated by Gen Pharma Holdings LLC (Florida) and assigned to ForwardVue in May 2021. The pitch deck presents both expired patents as "Franklin IP" on slide 11 without disclosing the separate inventor origin of '826. US 8,614,235's Claim 1 covers a "sterile, aqueous suspension formulation free of organic solvents comprising about 0.1 to about 2% w/v of suspended solid microparticulates of CAI ... wherein the ocular administration is by intravitreal injection." FVP-002 is a PLGA bioerodible implant, not an aqueous suspension. The '235 patent did not cover the lead-asset formulation design even when in force; its expiry formalizes a coverage gap that existed throughout the patent's active life.

5.3 Freedom to Operate

This report does not assess FTO at full depth. Two prior-art surfaces show at the screening level: a Chinese patent application covering carboxyamidotriazole orotate in AMD, and the broader NCI/King/Tactical Therapeutics CAI lineage. Both touch ForwardVue's mechanism and formulation claims. No cleared FTO opinion appears in the public record.

6.1 Verified Credentials

Alan J. Franklin, MD/PhD, founded the company and runs it as CEO as of March/April 2026. His LinkedIn headline reads "CEO, ForwardVue Pharma," but the Experience entry still reads "Founder, ForwardVue Pharma (Oct 2019 – Present)," and no press release announces the transition. Franklin trained as a vitreoretinal surgeon and holds a PhD in molecular physiology. He served as Chief Medical Officer at RFE Pharma from 2005 through October 2019 — fourteen years on the same molecule.

Bob H. Katz (President & CEO, Director, July 2021 – March 2026) built ForwardVue's operational structure for four years and nine months. His April 2026 LinkedIn post announced his Applikate Technologies CEO role: "I am excited to share that I have joined the outstanding team at Applikate Technologies as CEO." Applikate is a digital pathology hardware/software company founded 2013 by Richard Torres MD/MS (Yale pathologist) and Michael Levene PhD, with patented CHiMP (Clearing Histology with MultiPhoton Microscopy) technology that images intact whole tissue specimens, eliminating slide preparation. Katz replaced founder Torres as CEO in April 2026 — a domain shift from ophthalmic drug development to digital pathology, consistent with Katz's prior Class III PMA / 510(k) device track record. No formal prnewswire/businesswire release accompanied the transition. Katz remains co-inventor on WO 2025/075991 and a named director in the 2022 Form D. His LinkedIn ForwardVue entry is dated as ended (Jul 2021 – Mar 2026); the deck still presents him as President & CEO on slide 17. His departure leaves Franklin as the only principal managing science, operations, regulatory strategy, and investor relations.

Amir Shojaei PharmD/PhD departed the ForwardVue Executive Board in January 2025 to become Chief Scientific Officer at Harrow Inc. (NASDAQ: HROW), as documented in the Harrow press release of 2025-01-07. The deck still lists him as Executive Board Member — sixteen months stale at the time of this review.

Rishi P. Singh MD, FASRS, named on the Clinical Advisory Board, was appointed Chair of Ophthalmology at Mass Eye and Ear / Mass General Brigham / Harvard Medical School effective 2025-11-10 (Harvard press release). The deck still lists him at Cole Eye Institute (Cleveland Clinic). Further, the deck slide 18 bio for Singh reads "California Retina Consultants, Macula Society, Board Member ASRS, Co-Editor Retina Today" — identical to the bio shown for Robert Avery MD on the same slide. Singh has no California Retina Consultants affiliation at any point in his career and is not Co-Editor of Retina Today; those credentials belong exclusively to Avery (californiaretina.com, retinatoday.com). This is a copy-paste error on slide 18: Singh's actual credentials (Cole Eye Institute → Mass General Brigham Chair; ASRS board; Macula Society; Retina World Congress founder; 300-plus publications) are independently distinguished, and the deck error attributes Avery's institutional affiliation to him.

Christie Markowitz has served as Board Observer since 2020 (six-plus years) and does not appear on any deck slide. Her LinkedIn profile shows Senior Marketing Director / HCP Lead Ophthalmics for Xiidra at Shire (Mar 2016 – Dec 2018), Takeda (Jan – Jun 2019), and Novartis (Jul – Nov 2019, via Xiidra acquisition). She is currently Principal at Markowitz Strategic Group (Nov 2019 – Present) and serves on two other boards: Holland Foundation For Sight Restoration (Director 2025–Present, Observer 2019–2025) and Humonix Biosciences (Director Jun 2024–Present). Her Xiidra HCP-launch experience and US ophthalmic go-to-market profile are the strongest commercial-strategy credentials on or adjacent to the ForwardVue team — yet she remains undisclosed in the company's investor materials.

Christopher (Chris) Riemann MD holds five concurrent commercial board seats alongside full-time clinical and fellowship duties.

6.2 Publication Record

Franklin's retinal CAI publication record spans 2005–2025. The TVST 2025 paper (PMID 40131299) is the most recent peer-reviewed output and the primary scientific evidence for FVP-002. All retinal CAI publications trace to UAB-Grant-Franklin lab affiliates or the earlier Doheny/USC group — no third-party laboratory has published independent retinal CAI replication.

6.3 Flags

Four flags need explanation at the screening call: the CEO transition is undocumented (no press release, no formal filing); the deck is sixteen months stale on Shojaei and six months stale on Singh; the 2022 Form D names Maturi and Timmons as Directors, but the deck slide 17 board roster omits them and shows them only on the CAB; and slide 18 contains a CAB-bio copy-paste error between Singh and Avery.

The forwardvuepharma.com website is a three-page GoDaddy-builder site (home, about, contact). Six of nine tested URL paths return 404 (/pipeline, /science, /team, /news, /publications, /press — all absent). The copyright stamp reads 2019 — seven years stale. The homepage mailto link targets "fowardvuepharma.com" (missing letter "r"); the contact heading reads "inquires" instead of "inquiries." The site never uses the strings FVP-002, CAI, carboxyamidotriazole, bioresorbable, or implant — the lead asset is described only as "a novel long acting ORAI1 blocker." Investor materials describe a different program identity than the public-facing website. The website's "durable administration up to 12 months" claim also exceeds the deck's own six-month upper-bound durability framing and has no support in the primary literature.

7.1 Capital Raised vs. Claimed

SEC EDGAR records two Form D filings under Rule 506(b) for ForwardVue Pharma (CIK 0001828951):

• 2020-10-22 (accession 0001828951-20-000002): $4,000,000 offered; $0 sold of record. Use of proceeds discloses $50,000 for repayment of a bridge loan from an executive officer. Signed Alan Franklin, CEO.
• 2022-11-03 (accession 0001828951-22-000001): $1,000,000 offered; $0 sold of record. Securities type: Equity + Debt. Signed Bob Katz, CEO.

Neither Form D carries an amendment. Rule 506(b) requires annual amendments when an offering remains open more than twelve months. The absence of any amendment to the 2022 filing — now more than three years old — leaves two possibilities: the company closed sales and failed to file required amendments, or the deck's $1.5M seed claim refers to instruments (convertible notes, SAFEs) that the company does not classify as equity sales requiring Form D amendment. Either explanation needs verification.

Total SEC-verified capital raised: $0. Deck-claimed seed raised: $1.5M. The discrepancy is material and must close before term-sheet.

7.2 Cash Runway

No verified claims in this category. Private company with no public financial filings.

7.3 Insider Transactions

The 2020 Form D discloses $50,000 from offering proceeds applied to repayment of a bridge loan from an executive officer. The filing does not name the executive officer, but Franklin was the sole CEO and signer at that date.

8.1 FDA Precedent

Intravitreal PLGA bioresorbable implants have one direct FDA precedent: Ozurdex (dexamethasone implant, Allergan), FDA-approved for macular edema following branch or central retinal vein occlusion and later for non-infectious posterior-segment uveitis. Ozurdex is the structural and regulatory comparator ForwardVue is implicitly tracking. The specific Ozurdex pivotal-program designs and enrollment figures are deferred to a focused FDA-precedent pull before any pivotal-design discussion with management.

8.2 Designation Status

No verified claims in this category. ForwardVue has not disclosed any orphan drug, fast track, or breakthrough therapy designation in public records.

8.3 Approval Path

The deck plans a single-arm first-in-human DME study followed by a Series A to fund the pivotal program. A small-cohort safety/PK FIH plausibly establishes the IND, but it will not generate the "significant value inflection" the deck promises without an active control arm. The regulatory path from FIH to approval in wet AMD or DME — the deck's stated primary indications — requires at minimum two adequate and well-controlled trials. Neither the deck nor the public record shows a pre-IND endpoint strategy discussion with FDA. The Phase 2 trial announced in July 2021 has not registered on ClinicalTrials.gov after four-plus years.

9.1 Verified TAM

The global AMD therapeutics market reached $11.21 billion in 2024 and is projected to grow to $17.99 billion by 2030 at an 8.2% CAGR (Grand View Research). The deck-cited "$25B Global Retinal Disease Market by 2028" aggregates retinal indications beyond AMD; ForwardVue's wet AMD/DR/DME positioning maps to a portion of this aggregate, and the AMD-specific figure is the more disciplined anchor. The pitch's TAM math is directionally supportable but its sourcing is corporate investor decks (Tier 3); independent market-research firms (Grand View, IMARC, GMI Insights) place the AMD-only market near eleven billion dollars in 2024 and the broader retinal drugs market at twenty-two billion in 2024 growing to thirty-two billion by 2030 (Strategic Market Research).

A counter-current matters more than the headline: the global anti-VEGF therapeutics sub-market is projected to decline at -2.3% CAGR through 2030 as ranibizumab and bevacizumab biosimilars erode branded pricing (Grand View Research). The FVP-002 positioning as a VEGF-independent mechanism is, on this view, both opportunity and threat — opportunity because biosimilar pressure widens room for differentiated mechanisms; threat because the dollar pool that pays for branded innovation is shrinking, and a sustained-release CAI implant must compete on convenience economics against biosimilar Eylea and biosimilar Lucentis priced for value.

9.2 Prevalence Data

Global AMD prevalence reached 196 million patients in 2020 and is projected to grow to 288 million by 2040 as populations age (Wong 2014, Lancet Global Health, PMID 25104651). In the United States, an estimated 19.83 million Americans aged 40 and older lived with AMD in 2019, of whom 1.49 million had vision-threatening (late-stage) disease (Rein 2022, JAMA Ophthalmology, PMID 36326752; CDC VEHSS). Wet (neovascular) AMD accounts for approximately 10% to 15% of AMD cases (StatPearls). Annual US economic burden of late-stage AMD has been estimated at $49.4 billion, with productivity loss the largest single component at 42% (Paudel 2024, PMC12316190).

The deck's slide 5 framing of "800K nAMD patients receiving treatment" is mathematically consistent with the US wet AMD population — applying the verified 10–15% wet-AMD share to the US AMD prevalence (19.83 million) and then narrowing to the actively-treated subset reaches the high-six-figure to low-seven-figure range the deck cites. The 800K figure is plausible; the deck's only-sourced support is corporate investor decks rather than CMS or ophthalmology registry data.

9.3 Standard of Care & Pricing

Anti-VEGF dosing burden is the differentiator FVP-002 must beat. Real-world wet AMD patients receive a mean of about 5 anti-VEGF injections per eye per year, with first-year recommended ranges of 6 to 8 injections and label-maximum monthly dosing reaching 12 per year (Retina Today / MacCumber 2020 IRIS Registry). The deck's slide 4 "6, 8, 12 injections per year per treated eye" reflects this real-world-to-label-maximum range and is verified.

Branded incumbents anchor the pricing context. Eylea HD (aflibercept 8 mg, Regeneron) carries WAC at the high end of branded anti-VEGF and combined Eylea + Eylea HD US net sales totaled $5.97 billion in FY2024, with Eylea HD contributing $1.20 billion (Regeneron 4Q24 earnings). Vabysmo (faricimab, Roche) generated CHF 3.9 billion in global FY2024 sales. These two franchises define the durability bar FVP-002 must clear: Eylea HD extended its label from every 12–16 weeks to every 24 weeks in April 2026, and Vabysmo carries up to a 16-week (4-month) interval per its label. A "twice per year" implant must beat 24-week Eylea HD on convenience or match it on convenience while differentiating on mechanism — the deck's framing leans on the mechanism difference, but the convenience gap to incumbents has narrowed.

10.1 Competitor Stage Map

ForwardVue competes in a category dominated by established anti-VEGF biologics and one approved intraocular sustained-release system. Aflibercept (Eylea, Regeneron) and ranibizumab (Lucentis, Genentech) are the historical standard of care in wet AMD and DME. Eylea HD (aflibercept 8 mg; BLA 761355, FDA 2023-08-18) extended its label in 2025 to 8 mg every 4 weeks for the first three doses, followed by once every 8 to 16 weeks; an investor release notes that extended dosing intervals of once every 20 weeks (+/- 1 week) may be considered after one year of successful response. Combined Eylea + Eylea HD US net sales reached $5.97 billion in FY2024. Vabysmo (faricimab, Roche; BLA 761235, FDA Jan 2022) introduced a bispecific anti-VEGF/anti-Ang-2 with a Q16W maximum interval per label and generated CHF 3.9 billion in global FY2024 sales. Susvimo (Genentech, ranibizumab 100 mg/mL via port delivery; BLA 761197, FDA 2021) is the closest structural comparator to FVP-002's sustained-release positioning, with a 24-week refill interval per the 2025 label.

Brolucizumab (Beovu, Novartis) is the cautionary precedent — an FDA-approved single-chain anti-VEGF whose label the FDA updated in June 2020 to add retinal vasculitis and vascular occlusion warnings, after which uptake stalled. The Beovu episode is the standing reminder that new IVT agents can accumulate immune-mediated safety findings post-approval, and that any FVP-002 first-in-human study must be designed for that surveillance.

Two adjacent precedents inform the landscape. Gyroscope Therapeutics (acquired by Novartis 2022) developed GT005/PPY988, an AAV2 subretinal CFI gene therapy for geographic atrophy. Novartis discontinued the program 2023-08-24 citing futility per an independent DMC review: "the decision was taken to terminate the study and the GT005 program ... futility criteria had been met for the HORIZON study (GT005-03)" (Veeva CTV / Novartis IR). Syfovre (Apellis, pegcetacoplan; NDA 217171, FDA 2023-02-17) is approved for GA secondary to dry AMD with dosing on a 25-to-60-day interval per the FDA label.

Slide 15 of the pitch deck contains four documented errors. Opthea (sozinibercept) is shown as an active 2023 program; the Phase 3 COAST trial failed and Opthea suspended development on 2025-03-26 ("the COAST trial did not meet its primary endpoint of mean change in best-corrected visual acuity ... Opthea is suspending further development activities for sozinibercept" — Opthea press release). Restoret (EYE103, EyeBio/Merck; NCT05919693) is labeled as a "control arm comparator" in the AMARONE study; ClinicalTrials.gov records EYE103 as the experimental intervention, and Merck acquired EyeBio for $1.3 billion in 2024. The AMARONE nAMD cohort enrolled five patients per ClinicalTrials.gov — too few for any benefit/no-benefit conclusion. Beovu (brolucizumab, Novartis) was FDA-approved on 2019-10-07, not 2018 as the chart implies. The slide-15 chart also labels Eylea HD's targets as "VEGF-B, PlGF," but the FDA-approved Eylea HD label specifies aflibercept binding to VEGF-A and PlGF — not VEGF-B. The chart further claims GT005 was "fast-tracked May 2024" — eight months after Novartis discontinued the program in August 2023.

10.2 Differentiator Durability

ForwardVue's differentiating claims rest on two pillars: VEGF-independence (mechanism differentiation) and sustained-release duration (convenience differentiation). The mechanism differentiation is the more durable of the two if the FIH trial establishes human proof of concept in anti-VEGF-refractory patients — a study design the deck does not specify. The duration claim (6–12 months) is the weaker pillar: the published evidence supports 4 months with modest confidence; the 6-month framing requires in-vivo data that does not yet exist.

11.1 Contradicted Findings

Eleven primary findings directly contradict deck claims:

11.2 Unsupported Claims

Three claims could not confirm against any external primary source and require management response:

1. "6-month sustained release" / "twice per year." The TVST 2025 paper measures to 56 days in vitro and 120 days in vivo. The deck's 6-month framing is a Discussion-section forward extrapolation from those data, not a measured result.

2. "Pre-IND Meeting Consensus." FDA pre-IND meeting minutes remain non-public until after IND filing. No independent confirmation of meeting date, type, or outcome is obtainable from public records.

3. "Multiple Strategics with Demonstrated Interest" (Genentech and others — deck's partner slide). Logo walls do not imply contractual engagement. No term sheet, NDA, or partnership announcement appears in the public record.

11.3 Risk Severity

Risks that would end the program — IP failures (four separate failures):

1. US 8,614,235 statutory term-end. The 20-year statutory term expired 2025-09-26; USPTO formally recorded the lapse 2026-01-26. Revival is moot — no remedy exists.
2. US 9,629,826 early lapse. The 7.5-year (8th-year) maintenance fee due 2025-04-25 was unpaid; USPTO recorded the patent expired 2025-06-02. Roughly ten years of statutory term (to 2035-10-15) forfeited. A 37 CFR 1.378(b) revival petition remains possible but restores uveitis-indication coverage, not FVP-002 lead-asset coverage.
3. WO 2025/075991 missed national-phase entry — CONFIRMED. The 30-month US national-phase deadline of 2026-04-03 passed with no 371C event on USPTO ODP record as of 2026-05-11. A late-entry petition under 37 CFR 1.137 (unintentional delay, no hard cutoff) remains technically available; none appears on record. FVP-002 lead-asset US protection depends entirely on this petition succeeding.
4. US 12,594,262 covers off-thesis route. The only in-force US patent (granted 2026-04-07; adjusted expiration 2043-05-15) covers the CAI nanoemulsion formulation for inflammatory optic neuropathies and AMD — not the lead implant. The granted nano patent does not protect FVP-002.

The Katz inventorship exposure on WO 2025/075991 (35 U.S.C. 102(f)) is a secondary IP concern. If Katz's inventive contribution to the implant device was substantial, post-departure obligations need documentation; if his contribution was ornamental, his name on the inventor list creates invalidity risk.

Risks that require management action but are not program-ending:

CEO transition governance must formalize — filings, board minutes, and any investor agreements need to document Franklin as CEO. The $0 Form D versus $1.5M deck capital gap must close with cap-table documentation before term-sheet. The deck must remove Katz, Shojaei, and Singh's stale affiliations and correct the slide-18 CAB-bio copy-paste error before the next investor meeting. Slide 15's competitive chart needs material revision (Opthea, Restoret, Beovu year, GT005 status, Eylea HD targets).

Risks structural to the stage:

Single-lab publication record at the time of the TVST 2025 paper — though three earlier independent ocular CAI papers exist (Hoffmann 2004 PMID 15185118 Leipzig; Hoffmann 2005 PMID 15814468 Leipzig; Cruysberg 2005 PMID 16340533 Emory), corroborating the broader retinal CAI mechanism. Pre-IND endpoint strategy: no verified FDA feedback in the public record. The planned small-cohort FIH design, while clinically reasonable for safety/PK, will not generate value-inflection data without an active control arm.

12.1 Platform Beyond Lead

ForwardVue holds one granted US patent — US 12,594,262 B2, issued 2026-04-07 — covering CAI nanoemulsions for optic neuropathies and AMD, with adjusted expiration 2043-05-15. The granted patent traces to application US 17/785,842 (pre-grant publication US 2023/0024928 A1) and to PCT WO 2021/127407 A1. The indication is distinct from the lead FVP-002 wet AMD/DME implant program. This off-thesis grant shows that the founding team has continued formulation work outside the lead implant route and now holds enforceable US protection on the alternative. The inventor list — Franklin, Laurent Balenci, Srikanth Kakamanu, and Robert Dempsey — runs broader than the implant PCT, suggesting external collaborators on the nanoemulsion program.

12.2 Repurposing Potential

CAI's VEGF-independent mechanism hypothetically extends to any neovascular indication where SOCE channel blockade is therapeutically active. The NCI oncology prior program tested CAI in renal cell carcinoma, glioblastoma, and NSCLC — three solid-tumor indications where anti-angiogenic approaches validate. The FVP-002 route shift to intravitreal delivery narrows the indication; it does not widen the platform. Systemic repurposing would require returning to the oral-delivery route that failed in Phase 3 NSCLC.

12.3 Acquirer Profile

No verified claims in this category. The VEGF-independent mechanism could attract acquisition interest from a sponsor seeking to address anti-VEGF non-responders in a large wet AMD franchise (Regeneron, Roche, Novartis), but at the pre-IND stage with no in-force US patents and an unresolved IP reset, the asset is not acquirable on terms that would benefit early investors.